B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

BACKGROUND: B cell depletion with rituximab (RTX) is approved for treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitides (AAV). Recently, RTX has been shown to be effective in AAV maintenance therapy, but an optimal RTX treatment schedule is unknown and the time to B cell repopulati...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Res Ther
Autors principals: Thiel, Jens, Rizzi, Marta, Engesser, Marie, Dufner, Ann-Kathrin, Troilo, Arianna, Lorenzetti, Raquel, Voll, Reinhard E., Venhoff, Nils
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5437549/
https://ncbi.nlm.nih.gov/pubmed/28521808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-017-1306-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars